SEC Form 4 · accession 0001209191-15-043845
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Charles Lubner
Officer — SVP and CFO
Period of report
May 14, 2015
Accepted (ET)
May 18, 2015 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 14, 2015 | M | 7,684 | $2.03 | A | 86,954 | D | |
| Common StockF1,F3 | May 14, 2015 | S | 7,684 | $39.28 | D | 79,270 | D | |
| Common StockF1 | May 14, 2015 | M | 7,316 | $2.03 | A | 86,586 | D | |
| Common StockF1,F3 | May 14, 2015 | S | 7,316 | $39.28 | D | 79,270 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F4 | $2.03 | May 14, 2015 | M | 7,684 | D | — | Sep 27, 2020 | Common Stock | 7,684 | 0 | D |
| Employee Stock Option (right to buy)F1,F5 | $2.03 | May 14, 2015 | M | 7,316 | D | — | Jun 5, 2022 | Common Stock | 7,316 | 27,043 | D |
Explanation of responses
- F1The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2015.
- F2The amount of securities beneficially owned by the reporting person following the transaction reported on this Form 4 reflects the purchase by the reporting person of 402 shares of common stock on November 17, 2014 and 405 shares of common stock on May 14, 2015. Both of these purchases were done under the issuer's 2014 Employee Stock Purchase Plan ("ESPP"). The shares purchased in November 2014 under the ESPP were inadvertently omitted from the amount of securities beneficially owned that were reported on the Form 4 filed by the reporting person on January 9, 2015.
- F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $38.03 to $39.89 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4This option is fully vested.
- F5This option vests as to 6.25% of the shares on September 6, 2012 and further vests as to 6.25% of the shares at the end of each of successive three-month period thereafter until June 6, 2016.